Use

The Primary Membranous Nephropathy Diagnostic Cascade is significant in distinguishing primary from secondary membranous nephropathy using an algorithmic approach. It monitors patients with membranous nephropathy who have very low antibody titers and screens for anti-phospholipase A2 receptor antibodies, which are highly specific for diagnosing primary membranous nephropathy. Approximately 70% to 75% of patients with primary membranous nephropathy test positive for anti-PLA2R antibodies. Changes in antibody titer often precede shifts in clinical status, offering predictive insights into clinical remission, relapse, or transplantation-related risks.